An appeals court revived an antitrust suit against Sanofi, finding the company erred in improperly listing a patent in the US Food and Drug Administration's Orange Book since the patent did not mention Lantus SoloSTAR (insulin glargine injector pen), the drug for which it submitted a supplemental new drug application.
In a 13 February decision in In Re: Lantus Direct Purchaser Antitrust Litigation, the US Court of Appeals for...





